Q&A with Paul Weiss's Andrew Forman

06 March 2017

Q&A with Paul Weiss's Andrew Forman

Andrew Forman

Andrew Forman, a partner at Paul Weiss Rifkind Wharton & Garrison, has been part of the team at the centre of the Anthem/Cigna merger fight, but it is just the latest healthcare matter on his resume. While his headline-grabbing representations in private practice range from the US Airways/American Airlines tie-up to Eli Lilly's acquisition of Novartis Animal Health, as an attorney in the Mergers I shop of the Federal Trade Commission’s Bureau of Competition, he scrutinised deals in the pharmaceutical and medical device sectors, as well as others.